Pulmatrix Mulls Divestment Of Clinical Assets, Proprietary iSPERSE Technology As Part Of Proposed Merger With Cullgen

As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule drugs to the lungs by inhalation to treat migraine and respiratory diseases

Pulmatrix Currently Seeking Divestment of Clinical Assets and Proprietary iSPERSE™ Technology